Current classifications of OMD assign one state per patient. But within the same patient, lesions respond, persist, and progress on divergent paths. We propose metastatic trajectories – a lesion-level framework to guide local systemic therapy in metastatic NSCLC. 📄 @JCO_ASCO

what a great city

New in @JCO_ASCO from @IyengarPuneeth and colleagues: proposing "metastatic trajectories," a lesion-level framework for metastatic NSCLC, recognizing that different metastases within the same patient can evolve along divergent biological paths. Read more: ascopubs.org/doi/10.1200/JCO…

Just published in the #GreenJournal: Leveraging the potential of prospective registries for radiation oncology research: 5-year experience from the @EORTC-ESTRO #radiotherapy infrastructure for Europe (E2-RADIatE) project 👉 Read the abstract: bit.ly/4vClkO9

Excited to share our latest paper out today in @CCR_AACR, led by first authors Ayesha Hashmi, Jessica Linford and Pradeep Chauhan (@pradeep198212) in my lab @MayoRadOnc @MayoCancerCare @MayoClinic. aacrjournals.org/clincancerr…

The primary is the source of first progression in >50% of cases of #lungcancer patients, and TRACERx showed us that in 32% of NSCLC the primary polyclonally seeds metastases. In our @IASLC consensus, now in JTO shorturl.at/GzAe2, makes the case for eradicating it with #radiotherapy. The EGFRm phase III data are the most compelling OS 34.4 vs 26.2 months with TKI RT. There are still unresolved questions in the non-AGA population. We are opening the phase III PRIME-LUNG trial shorturl.at/26apO @TROGfightcancer @TOGAANZ to answer this question! #radonc

New data on #oligometastatic #ProstateCancer from #ESTRO26: 1️⃣EXTEND: ctDNA= a powerful prognostic tool, though MDT benefits patients regardless of ctDNA status 2️⃣OLIGOPELVIS-2: Salvage nodal RT to para-aortic nodes has manageable long-term side effects. 👉bit.ly/4oi7zSu

Detecting lung cancer 5 years before it happens, in @CellCellPress courtesy of the @CharlesSwanton group. Astonishing translational work ! cell.com/action/showPdf?pii=…

What does chemo add to immunotherapy in pts w/ PD-L1-high NSCLC? In our meta-analysis of 24 trials w/ reconstructed individual patient data, we observed a meaningful improvement in both median PFS (11.3 vs 6.8 months, HR 0.74) and OS (29.2 vs 19.8 months, HR 0.67) w/ chemo-ICI.

What a happy coincidence! While presenting intracranial efficacy data from DeLLphi-304 in #ASCO26, #Tarlatamab was officially approved in EU!! ✅ In ITT: CNS mPFS NR vs 7.8 m, HR=0.54 ✅ In BM per mRANO: CNS mPFS 6.5 vs 4.2m, HR=0.4 ✅ mOS=13.9 vs 6.8, HR=0.51, independent of baseline BM! A new SoC, hope that all #SCLC patients will soon have access!! #some #LCSM @OncoAlert @OncBrothers @OncLive @PortalOnconews @SclcSMASHERS @myESMO @ASCO @IASCL @PeerView

Negative phase III trial of concurrent thoracic RT in ES-SCLC receiving chemoimmunotherapy. TRT was initiated early (between cycles 2 and 3), and failed to improve outcomes: • Median OS 10.0 vs 11.8 months • No improvement in response rate • More adverse events and treatment-related deaths While disappointing, these results should not be extrapolated to all consolidative TRT strategies. One key difference from SAKK 15/19 is timing: RT here was delivered concurrently with ongoing chemoimmunotherapy, whereas SAKK 15/19 administers TRT after completion of induction treatment and no major toxicity was detected Perhaps the lesson is not that thoracic RT has no role, but that timing matters. pubmed.ncbi.nlm.nih.gov/4134… #ASCO26 #SCLC #LungCancer #Radiotherapy

Excellent poster by @militspatel stellar student in our group, on genomic determinants of metastatic urothelial #cancer @ASCO #asco2026 Thank you Drs @IyengarPuneeth @HimanshuNagarMD @jjnaylor02 @jonas_willmann for guidance

ASCO2026: Asymptomatic brain met EGFR/ALK NSCLC any benefit upfront cranial RT on this Randomized trial? - Upfront RT ↑↑ brain control, no benefit PFS, OS - Selection criteria high risk (e.g. larger size) for upfront RT is key ascopubs.org/doi/10.1200/JCO…

🫁 Metastatic trajectories in NSCLC: redefining local systemic therapy through disease evolution! @JCO_ASCO ascopubs.org/doi/pdf/10.1200… ▪️ Genomics ctDNA radiomics functional imaging ▪️ Defines progression by pace, pattern, organotropism & resistance mechanisms ▪️ Adaptive strategies: escalate, switch, consolidate or locally ablate ▪️ Could reshape biomarker-driven platform trials in mNSCLC Not all metastases follow the same road…some take very different “trajectories” 🚦 @OncoAlert @OncoReporte @myESMO @_SEOM @LungCancerRx @Lung_Cancers @gecp_org

What a beautiful message at the end of @Mat_Guc presidency at #ESTRO26 passing the torch to @BarbaraJereczek! See you at #ESTRO27 in Milano, 21-25th of May 2027.

🎥 Out of #ESTRO26: Can a simple blood test change the definition of oligo metastases? 🩸 🧬 Researchers found that tracking circulating tumour DNA (ctDNA) could change how we manage #oligometastaticcancer 👇@AlexSherryMD

The OLIGOMA trial results are out! Breast #SBRT shows promising outcomes with stable patient quality of life. Dr David Krug 🇩🇪 breaks down: 💡 Motivation for this breast cancer SBRT approach 🎯 Patient tolerance 🚀 Next steps 🎥 Watch 👇 #ESTRO26 #RadOnc #BreastCancer

RT @Icro_Meattini: Congratulations @NAndratschke and the whole team - presenting @EORTC @ESTRO_RT E2-Radiate ReCare cohort to assess adequa…

@LukaszKuncman presenting maybe the most important messages for the radiation oncology community: words matter #ESTRO26

Largest prospective SBRT registry in the world! #ESTRO26

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Five-Year Follow-Up of the SABR 5 Trial: Primary Toxicity Analysis of Stereotactic Ablative Radiotherapy for Up to Five Oligometastases Presenter Robert Olson 🇨🇦 SABR-5 is a population-based phase II trial evaluating long-term toxicity of SABR for patients with up to five oligometastases. Among 380 patients treated across a provincial program, five-year follow-up showed low rates of high-grade toxicity, with no late emergence of grade ≥4 events. Most late toxicities were low grade and often persistent rather than new. These findings provide reassurance regarding the long-term safety of SABR in routine clinical practice. #RadOnc @ESTRO_RT @yasemin09896924 @LindaMrissa @christian_roenn @Valeriadionisi @gerryhanna @clchiang_hk @mtugceyilmaz @B_Tomasik @gmpetrianni @CiroFranzese1 @Atem84 @piet_ost @brachyexpert @BlanceS90 @The_PT_Explorer @BarbaraJereczek @Mat_Guc @ZilliThomas @AnnaKirby17 @PBlanchardMD @achoud72 Pinging OA faculty @MKnoll_MD @_ShankarSiva @Icro_Meattini @seanmmcbride @NiuSanford @nataliagandur @acampsmalea @to_be_elizabeth